<DOC>
	<DOCNO>NCT00003410</DOCNO>
	<brief_summary>RATIONALE : New image procedure use gadolinium texaphyrin MRI may improve ability detect extent glioma . PURPOSE : Phase I trial study effectiveness gadolinium texaphyrin use MRI-guided surgery treat patient high-grade glioma .</brief_summary>
	<brief_title>Motexafin Gadolinium With MRI-Guided Surgery Treating Patients With High-Grade Gliomas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose gadolinium texaphyrin tumor retain contrast agent MRI guide neurosurgery patient radiological diagnosis high grade glioma . I . Determine intratumoral pharmacology quantitative pharmacokinetics gadolinium texaphyrin use MRI image patient . II . Develop scale relate MRI signal characteristic intratumoral gadolinium texaphyrin absolute intratumoral level gadolinium texaphyrin patient . III . Investigate distribution gadolinium texaphyrin high grade glioma comparison biologically active tumor delineate elevated choline-containing material detect proton magnetic resonance spectroscopic image . OUTLINE : This dose escalation study . Patients receive gadolinium texaphyrin IV infusion 20 minute 2 hour prior magnetic resonance imaging surgery . The maximum tolerated dose single dose gadolinium texaphyrin determine cohort 3 patient treat one five escalating dos . Patients cohort follow minimum 4 week next cohort begin . If good contrast enhancement assess fourth dose level ( cohort 4 ) , dose escalation stop . Patients follow day 1 2 , week 1 , 2 , 4 , 3 month surgery . PROJECTED ACCRUAL : A total 6-18 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Radiological diagnosis probable high grade glioma , biopsy proven high grade glioma , undergoing neurosurgery ( biopsy tumor resection ) interactive MRI guide control Must enhance cerebral lesion No radiological diagnosis metastasis due multiple lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % steroids Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Prothrombin time great 1.5 time upper limit normal ( ULN ) Active partial thromboplastin time great 1.5 time ULN Hepatic : Bilirubin great 2 mg/dL AST ALT great 2 time ULN Renal : Creatinine le 1.5 mg/dL Cardiovascular : No severe cardiac disease Pulmonary : No severe pulmonary disease Other : No significant life threaten disease No known glucose6phosphate dehydrogenase deficiency porphyria No active malignancy No intractable seizure Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Concurrent steroid allow Radiotherapy : Concurrent radiotherapy allow Surgery : See Disease Characteristics Other : At least 48 hour since prior MRI scan contrast No concurrent active agent investigational drug No concurrent use study treatment Concurrent antiseizure medication allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>